Healthcare Jun 20, 2022 11:53 AM (GMT+8) · EqualOcean
On June 20, an Xuyuan, a fourth generation sequencing enterprise, announced that it had completed a round B financing of nearly US $100 million. This round of financing is jointly led by AstraZeneca CICC medical industry fund and Yunfeng fund, followed by Cambridge capital, China investment and five source capital. The financing will be used to further optimize the sequencing technology of anxuyuan, build the production base of sequencer, and expand the commercialization, so as to help the iteration of the fourth generation sequencing technology of anxuyuan and accelerate the industrialization process. Let the lower cost, more efficient and convenient long reading and long sequencing products benefit more end users, and promote the development of life science and medical industry.

This text is a result of machine translation.